Table 1.

Clinical findings of patients with paraneoplastic NMOSD and AQP4 antibodies.

Patient	Age/sex	Tumor type (interval (months) NMOSD-tumor)	Presenting symptoms	Predominant neurologic syndrome	CSF	Spinal MRI: length of T2 lesion	Treatment	Outcome
1	49/M	NSCLC (+1)	Seizures rapidly followed by LETM	LETM	157 WBC/μL, protein: 103 mg/dL OCB: negative	medulla to L1	Steroids, IvIG	Improved. Death due to tumor
2	55/F	NSCLC (0)	Nausea and vomiting followed by LETM	LETM	42 WBC/μL, protein: 127 mg/dL OCB: negative	medulla to L1	Steroids, chemotherapy	Worse, relapse at 3 months
3	61/M	NSCLC (−1)	Myelopathy	LETM	0 WBC/μL, protein: 140 mg/dL OCB: not done	C3 to T8	Steroids, IvIG, radiotherapy	Stable. Death due to tumor
4	72/M	Squamous ca. oral cavity (+19)	Myelopathy	LETM	9 WBC/μL, protein: 47 mg/dL OCB: negative	C6 to T2	Steroids, AZA, chemotherapy, radiotherapy	Worse, 3 relapses in 24 months. Death due to tumor
5	73/F	Breast (−10)	Myelopathy	LETM	Unknown	C6 to T10	Steroids, chemotherapy, radiotherapy	Worse, relapse at 8 months. Death due to tumor

AQP4: aquaporin-4; AZA: azathioprine; ca: carcinoma; LETM: longitudinal extensive transverse myelitis; NMOSD: neuromyelitis optica spectrum disorder; NSCLC: non–small cell lung cancer; OCB: oligoclonal bands; WBC: white blood cells; IvIG: intravenous immunoglobulins; MRI: magnetic resonance imaging.